Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Axovant reports preliminary findings from expanded access treatment with AXO-AAV-GM1

Dec. 20, 2019

Imeglimin completes pivotal phase III program for type 2 diabetes in Japan

Dec. 20, 2019

Crinetics Pharmaceuticals describes new melanocortin MC2 receptor antagonists

Dec. 20, 2019

Rezolute reports phase I results for ultra long-acting basal insulin AB-101

Dec. 19, 2019

Inventiva reports phase IIa results on odiparcil for MPS VI

Dec. 19, 2019

Interim data presented from phase I/II study of RGX-121

Dec. 19, 2019

Homology reports initial data from phase I/II study of HMI-102 gene therapy in PKU

Dec. 18, 2019

D-amino-acid oxidase inhibitors discovered at SyneuRx International

Dec. 18, 2019

First patient enrolled in pivotal phase III InnovAATe study of Kamada's inhaled AAT

Dec. 17, 2019

BioMarin reports encouraging final phase III data for vosoritide in children with achondroplasia

Dec. 17, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...